Zolpidem Tartrate

酒石酸唑吡坦

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameZolpidem Tartrate
Drug Alias NameZolpidemum酒石酸唑吡旦唑呲呾唑吡旦佐沛眠 +[28
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor agonists
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsAutistic DisorderAutism Spectrum DisorderAttention Deficit Disorder with Hyperactivity +[13
Global Approved IndicationsSleep Initiation and Maintenance Disorders
Approved Indications in ChinaSleep Initiation and Maintenance Disorders
Original Approved Country/TerritoryFrance
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSerbia +[12
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active IndicationsAutistic DisorderAutism Spectrum DisorderSleep Initiation and Maintenance Disorders +[4
Inactive IndicationsAttention Deficit Disorder with HyperactivitySleepSubstance-Related Disorders +[9

Other Information

ATC CodeN05CF02